



THE UNITED INDUSTRY VOICE FOR AUSTRALIAN GENOMICS

March 2026 Newsletter

From discovery to delivery: the next phase of precision medicine

Dear members and friends,

February and March have been an intense and energising period across the genomics and precision medicine ecosystem, with national and international discussions focused on the next phase of implementation. And breakthroughs in patient access.

We would like to highlight the world first pan-tumour PBS listing announcement means that patients with advanced or metastatic cancers will be able to access subsidised immunotherapy based on clinical judgement rather than tumour type. It was encouraging to hear Minister Butler describe this as one of the most exciting announcements of his time in the portfolio. Congratulations to the BMS team and all involved in this achievement.

Across meetings including APOS, Path Update, the Canada-Australia Health Economics workshop, Rare Disease Day and the Cell and Gene Therapy Summit, a consistent theme emerged. The conversation around precision medicine is shifting. For many years the focus has been on scientific discovery and technological possibility. The question now is where we are in implementing precision medicine across health systems.

Precision oncology implementation

At the APOS meeting in Sydney, discussions among clinicians, researchers and industry reinforced this shift. Professor David Thomas reflected on Australia's world-first pan tumour immunotherapy PBS approval. The clinical discussion reinforced the importance of molecular profiling to guide treatment decisions to treat the right patient. There was also strong advocacy that comprehensive genomic profiling should become standard of care, beginning where the clinical need is clearest, including advanced and rare cancers.

International Health economics lessons

Steve Williamson from NICE shared insights on how health technology assessment and managed access programs such as the Cancer Drugs Fund and Innovative Medicines Fund support earlier patient access while real world evidence is gathered. We were also pleased to participate in the Canada-Australia Health Economics workshop, exploring how Canada has strengthened its HTA processes with learning systems to enable more timely patient access. These models offer practical lessons as Australia considers how to strengthen its own approaches to funding precision therapies.

Equity and the patient experience

Equity and access were also central themes across several events. InGeNA was proud to partner with ARCS Australia and DIA on the international **Cell and Gene Therapy Summit** in Sydney, where I chaired a session on Equity and Access bringing together national and international leaders to explore how Australia can advance both capability and equitable delivery in the evolving cell and gene therapy landscape.

Rare Disease Day, hosted by Genetic Support Network Victoria and chaired by our Consumer Advisory Group Chair and Board Director Monica Ferrie, highlighted the vision for rare disease care by 2035 and the role that new technologies, regulatory harmonisation and collaboration can play in improving access.

At **APOS**, The focus was no leaving no one behind. Professor Maree Toombs and Christine Cockburn shared about precision oncology reach communities too often left at the margins First Nations peoples, those with rare cancers, and Australians in non metro areas.

Growing clinical adoption

One of the strongest signals across the APOS and Oxford Nanopore Technologies meetings was the increasing engagement of clinicians and pathologists with genomic technologies. The clinical community is leaning in and asking how these tools can be integrated into everyday care. This is what traction in adoption looks like.

The role of collaboration

At InGeNA we are proud to represent the genomics and precision medicine industry and to work alongside clinicians, patient advocates, researchers and policymakers to accelerate this transition. Our members and consistently highlight three areas of value from InGeNA's work:

- strong access to government insights and decision-makers
- demonstrated policy influence through coordinated advocacy
- meaningful collaboration that helps reduce fragmentation across the genomics ecosystem

There is momentum across the field and a shared commitment to ensuring genomic advances translate into real improvements in patient outcomes.

The question is clear. ***How do we build the systems that turn precision data into***

precision care at scale?

I will be attending the **PTA Congress26** event in May. See registration links and more details in the Events section below.

Wishing everyone at the Rare Cancers Australia's Kosi Challenge an inspiring time – this is a wonderful cause to support.

A belated Happy International Women's Day to all of the incredible women across the ecosystem. We would like to congratulate Professor Tracey O'Brien, recognised as the NSW Premier's Woman of Excellence at the NSW Women of the Year Awards.

Best wishes

Erin

CEO, InGeNA

Recent Events



Canada-Australia Health Economics workshop - Feb 17th



Rare Disease Day on Feb 27, hosted by Genetic Support Network Victoria, chaired by our Consumer Advisory Group Chair and Board Director, Monica Ferrie.



Cell and Gene Therapy Summit - Feb 25th
in partnership with ARCS Australia and DIA



Oxford Nanopore User Group - March 5th

InGeNA Members and Partners News

A wonderful announcement - [link](#)

from two highly valued InGeNA members, *Genomical* and *Illumina*, who have entered into a licensing agreement enabling clinical laboratories to access Illumina's genomic analysis software through the Genomical® platform.

This will help laboratories deploy genomic testing programs faster and at lower cost while strengthening data governance and cybersecurity, scaling testing capacity, and supporting Australia's sovereign genomics capability by keeping more infrastructure onshore.

Eugene are hiring Head of Engineering

An engineering leader who's still close to the code - someone who wants to be in the work, not managing from a distance. You'll own our clinical genomics platform end-to-end, ship AI features in production, and work directly with the founders to shape the technical direction of the company. Remote-first, anywhere in Australia. **Apply [here](#)**

Industry News

24.01.26 CRISPR vs TIGR: The Genetic Upgrade You Didn't Know Was Coming

19.02.26 the brain drain killing American science

05.03.26 Genomic Therapy Matching in Rare and Refractory Cancers

Upcoming Events

PTA-C/26 Sydney | 27–28 May 2026

Brings clinicians, policymakers, researchers, patient advocates and industry together to explore practical pathways toward a more predictive, preventative and personalised healthcare system. www.ptacongress.com

The 49th **HGSA Annual Scientific Meeting** on 1-4 August 2026

at Te Pae, Christchurch New Zealand.

Early Bird Registration opens – February

Submissions

Please see our submission to the MRFF Research Program (February 2026) [Here](#)

[Join InGeNA NOW!](#)

New Membership options and partnering opportunities

Find out more with our Membership Brochures and online

Application forms [here](#)

 **nGeNA**



InGeNA Limited, 45 Brisbane Road, Suite 407 Level 4,
Mooloolaba, Queensland, 4557, Australia,

[Unsubscribe](#)

[Manage preferences](#)

Send free email today

HubSpot